Drug Trial Radar · NCT05686551
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
301
Actual
Start
Feb 3, 2023
Primary completion
May 14, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
Conditions
- Huntington Disease
Interventions
TominersenDrug
Tominersen will be administered at the dose and schedule specified in the protocol.
PlaceboDrug
Matching placebo administered IT, Q16W during the DB period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Period: Incidence and Severity of Adverse Events (AEs), With Severity Determined According to the AE Severity Grading ScaleTime frame: Up to approximately 36 months
- DB Period: Change From Baseline in Clinical Laboratory Results - Cerebrospinal Fluid (CSF) White Blood Cell (WBC)Time frame: Baseline visit (Day 1), and Months 4, 8, 9, 12, 16
- DB Period: Change From Baseline in Clinical Laboratory Results - CSF ProteinTime frame: Baseline visit (Day 1), and Months 4, 8, 9, 12, 16
- DB Period: Change From Baseline in Structural Magnetic Resonance Imaging (MRI) Assessing Any New Abnormalities Including Radiographic Features Consistent With Hydrocephalus and Other Relevant MRI Safety FindingsTime frame: Baseline, Months 4, 8, 12, 16 and up to approximately 36 months
- DB Period: Percentage Change From Baseline in Geometric Means of CSF Mutant Huntingtin (mHTT) Protein Levels at Month 9Time frame: Baseline, Month 9
- DB Period: Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores (non-U.S. Sites) at 16 MonthsTime frame: Baseline to 16 months
- DB Period: Change From Baseline in Total Functional Capacity (TFC) Scores (U.S. Sites) at 16 MonthsTime frame: Baseline to 16 months
- OLE Period: Incidence and Severity of AEs, With Severity Determined According to the AE Severity Grading ScaleTime frame: Up to approximately 29 months
- OLE Period: Change Over Time in Clinical Laboratory Results - CSF WBCTime frame: Up to approximately 24 months
- OLE Period: Change Over Time in Clinical Laboratory Results - CSF ProteinTime frame: Up to approximately 24 months
- OLE Period: Change From Baseline in Structural MRI Assessing Any New Abnormalities, Including Radiographic Features Consistent With Hydrocephalus and Other Relevant MRI Safety FindingsTime frame: Up to approximately 29 months
Locations
70 sites in 15 countries. Site status is shown where the registry gives one.
Uab Medicine
Birmingham, Alabama
Barrow Neurological Institute
Phoenix, Arizona
University of California Davis Medical System
Sacramento, California
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado
Georgetown University
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
University of South Florida
Tampa, Florida
Northwestern University
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
John Hopkins University School of Medicine
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Dent Neurological Institute
Amherst, New York
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas Health Science Center at Houston
Houston, Texas
EvergreenHealth Investigational Drug Services
Kirkland, Washington
Inland Northwest Research
Spokane, Washington
CINME
Buenos Aires, Argentina
Hospital Ramos Mejía
CABA, Argentina
INEBA
Capital Federal, Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Monash Medical Centre
Clayton, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Perron Institute for Neurological and Translational Science
Nedlands, Western Australia, Australia
Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck
Innsbruck, Austria
University of Alberta Hospital
Edmonton, Alberta, Canada
Montreal Neurological Inst
Montreal, Quebec, Canada
Rigshospitalet, Hukommelsesklinikken
København Ø, Denmark
CHU Angers, Batiement Larrey 2, Neurologie
Angers, France
Groupe Hospitalier Pellegrin
Bordeaux, France
Hopital Henri Mondor
Créteil, France
Hopital Roger Salengro Service de Neurologie
Lille, France
CHU de la Timone - Hopital d Adultes
Marseille, France
Hopital Gui de Chauliac
Montpellier, France
CHU Strasbourg Hpital Hautepierre
Strasbourg, France
CHU toulouse - Hôpital Purpan
Toulouse, France
Uniklinik RWTH Aachen
Aachen, Germany
Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie
Berlin, Germany
St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni
Bochum, Germany
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.